UroGen ahead of schedule completing UGN-102 NDA; Q2 revenue $21.8M, net loss $33.4M

UroGen Pharma Ltd.

UGN-102 NDA completion imminent; potential FDA decision as early as Q1 2025 assuming priority review.
Q2 JELMYTO net revenue $21.8M (+3% YoY); full-year revenue expected at lower end of guidance range.
Q2 net loss $33.4M ($0.91/share) vs $24.1M ($1.03/share) in Q2 2023; operating loss $25.8M.
Cash & marketable securities $241.3M at June 30; June public offering raised $107.5M gross.
Full-year operating expenses expected at higher end of guidance; R&D $15.4M, SG&A $30.1M in Q2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.